TO INNOVATIONS

SATURDAY 29 OCTOBER 2016 POSTER DISCUSSION SESSIONS
POSTER DISCUSSION SESSION 47 3 12:15-13:15 3 POSTER AREA HALL 2
MDR- AND ISONIAZID-RESISTANT TB: OUTCOMES
Chair: Carole Mitnick (United States of America) – Section: Tuberculosis
[PD-1071-29]
Treatment outcomes for multidrug-resistant tuberculosis patients under DOTS-Plus in developing counties: systematic review
and meta-analysis
Y M Mesfin (Ethiopia)
[PD-1072-29]
High treatment success in patients started on multidrug-resistant tuberculosis treatment in Kenya
H Huerga, M Bastard, M Kamene, S Wanjala, A Arnold, N Oucho, I Chikwanha, F Varaine (France, Kenya, United Kingdom)
[PD-1073-29]
Treatment outcomes among multidrug-resistant tuberculosis cases at a referral hospital for infectious diseases in Italy
G Gualano, R Urso, S Rosati, R Tonnarini, D Biagioli, G Matteucci, P Ghirga, S Murachelli, G Biava, D Goletti, E Girardi, G Ippolito, F Palmieri
(Italy)
[PD-1075-29]
Outcome of new cases of drug-resistant tuberculosis in Brazil
S Barbosa Codenotti, K Andrade, A Lobo, D Pelissari (Brazil)
[PD-1076-29]
Factors associated with treatment outcomes in a Brazilian isoniazid-monoresistant tuberculosis cohort
A Trajman, M Lisboa Bastos, F Dockhorn Costa, S Barbosa Codenotti, D M Pelissari, D Menzies (Brazil, Canada)
[PD-1077-29]
Treatment success rate of Programmatic Management of Drug-Resistant Tuberculosis in Himachal Pradesh, India: a retrospective study
T C Mahant, R Kumar, S Pundir (India)
[PD-1078-29]
Outcomes of retreatment cases of drug-resistant tuberculosis at the Indus Hospital, Karachi
R Batool, A Malik, H Hussain, Z Barry, S Butt, S Adnan, S Khan, N Salahuddin (Pakistan)
[PD-1079-29]
XDR-TB treatment outcomes in European regions of the Russian Federation
S Sterlikov, V Testov, I Vasilyeva, A Samoilova (Russian Federation)
[PD-1080-29]
Description of attributes of multidrug resistant tuberculosis cases in Afghanistan: a cross-sectional explanatory assessment
H K Amirzada, S D Mahmoodi, G Q Qader, M K Seddiq, M Isono, A Momand, M R Aloudal (Afghanistan)
[PD-1081-29]
Outcome in MDR-TB patients treated under the Revised National Tuberculosis Control Programme of India
A Janmeja, D Aggarwal, R Sharma (India)
POSTER DISCUSSION SESSION 48 3 12:15-13:15 3 POSTER AREA HALL 2
MDR TREATMENT OUTCOMES
Chair: Paul Nunn (United Kingdom) – Section: Tuberculosis
[PD-1082-29]
Impact of fluoroquinolone resistance on multidrug-resistant tuberculosis treatment outcomes: retrospective cohort study in Pakistan
A Ghafoor, A Latif, Z Toor (Pakistan)
[PD-1083-29]
Modelling the effect of reduced regimen duration for multidrug-resistant TB in Karakalpakstan, Uzbekistan
J M Trauer, J Achar, N Parpieva, A Khamraev, J T Denholm, A Mesic, D Falzon, E Jaramillo, P Du Cros, E S McBryde (Australia, United Kingdom,
Uzbekistan, Netherlands, Switzerland)
[PD-1084-29]
Treatment outcomes of pulmonary MDR-TB in the Tokyo metropolitan area, Japan
N Kobayashi, T Hattori, S Kato, J Takasaki, K Ohta (Japan)
[PD-1085-29]
Evaluation of the effectiveness and tolerability of two short-course treatments for multidrug-resistant tuberculosis in Niger
S Hassane Harouna, M B Souleymane, S Morou, I Boukary, S Attaher, Z Hamidou Harouna, A Piubello (Niger, France)
[PD-1087-29]
Novel treatment regimens for rifampin-resistant tuberculosis: linking specific regimen characteristics to expected population-level impact
E Kendall, S Shrestha, T Cohen, K Dooley, C Lienhardt, T Forissier, M Rich, D Dowdy (United States of America, Switzerland)
[PD-1088-29]
Outcomes for pregnant and postpartum women with drug-resistant tuberculosis and their infants in Belarus
A Skrahina, I Salonko, H Hurevich, A Skrahin (Belarus)
SATURDAY 29 OCT
26-29 OCTOBER 2016 - LIVERPOOL - UNITED KINGDOM
175